Bronchial Colonization With Fungi and Late Respiratory Acquired Pneumonia

Ventilator Acquired Pneumonia Clinical Trial

— CBF et PAVMt  

Official title:

Study of the Impact of Bronchial Colonization With Fungi in the Occurrence of Late Ventilator Acquired Pneumonia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01770015
• Other study ID #: 2011-A00767-34
• Status: Completed
• Phase: N/A
• Start date: November 2011
• Est. completion date: September 2016

Study information

• Verified date: November 2022
• Source: University Hospital, Grenoble
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Ventilator acquired pneumonia (VAP) are severe nosocomial infections. On the other side, bronchial fungi colonization is commonly observed in ICU; therefore, the investigators propose to study the role of bronchial fungi colonization on the occurrence of VAP taking into account the immune status of the patient and the antibiotic and antifungal treatments he has received.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 213
• Est. completion date: September 2016
• Est. primary completion date: March 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patient ventilated for at least 5 days

Exclusion Criteria:

• invasive infection Candida sp defined by : candidemia, isolation of Candida from a normally sterile site, candida pneumoniae.

Related Conditions & MeSH terms

• Pneumonia
• Pneumonia, Ventilator-Associated
• Ventilator Acquired Pneumonia

Intervention

Procedure:
• biological sampling
cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization
• sampling blood
HLA DR antigen, cytokines (IL 6 and 10), B-glucan
• endotracheal aspiration
fungi and bacteria endotracheal aspiration

Locations

Country	Name	City	State
France	Hospital University Clermont Ferrand Gabriel Montpied	Clermont-Ferrand
France	University Hospital of Grenoble	Grenoble

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Grenoble

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Onset of a late ventilator acquired pneumonia (VAP)		Participants will be followed for the duration of mechanical ventilation, an expected time frame that can go from 5 days to up to 8 weeks
Secondary	Onset of a pseudomonas aeruginosa associated VAP		Participants will be followed for the duration of mechanical ventilation, an expected time frame that can go from 5 days to up to 8 weeks
Secondary	Onset of late ventilator associated pneumonia associated to staphylococcus aureus		Participants will be followed for the duration of mechanical ventilation, an expected time frame that can go from 5 days to up to 8 weeks